Cancer CDK Inhibitor Market 2019-2029 - Pipeline Analysis, By Drug Type (Palbociclib, Ribociclib, and Abemaciclib), By Distribution Channel (Hospital Pharmacies, Online Pharmacies and Others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

According to the World Health Organization, the global burden of cancer was projected to increase from 10 million new cases in 2000 to 15 million in 2015 and based on this continuous rise it is estimated 9 million deaths and more than 11 million patients in 2030. There are three drugs available in the market under the mane Palbociclib, Ribociclib and Abemaciclib. These drugs are cyclin-dependent kinase (CDK) inhibitor that targets CDK4 and CDK6 cell cycle pathway with potential antineoplastic activity. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of the serine/threonine kinases CDK4/6 , as seen in certain types of cancer and causes cell cycle deregulation. However these drugs are side-effects too which include mild elevations in serum aminotransferase during therapy and to an unusual form of liver injury called pseudocirrhosis  caused by shrinkage of tumor metastases in the liver combined with desmoplastic changes and vascular damage that can be severe, progressive and even fatal. Cancer CDK Inhibitor Market accounted for US$ 6.0 billion in 2019 and is estimated to be US$ 16.1 billion by 2029 and is anticipated to register a CAGR of 10.4%.

Impact of Covid-19 pandemic on market

COVID-19 is an incomparable global health emergency that has disturbed almost every industries as ongoing research amplifies the research frame work to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. Product supply chain and transportation has also affected due to lockdowns everywhere.

Increasing prevalence of cancer patients

The increase in mortality and morbidity rates among patients is one of the driver of this market. For instance, according to WHO, there are approximately 14 million cancer incidence every year and the rates are constantly increasing. Almost 1.9 million new cancer cases are expected to be diagnosed in 2021.

High Unmet Medical needs for patients

Cancer patients are looking forward for some advancement in drugs. Further, a large number of companies are now investing into oncology markets to meet the needs of cancer patients. Such companies are contributing for introduction of new drugs with better functionality into market.

Side effects & Unreliable Efficacy

There are many side effects involved in the treatment of this disease. The most common side effect is neutropenia which is temporary and dose-dependent with the white blood count usually return when dose is interrupted or dose is reduce.

Fluctuation in Reimbursement policy by Government and Slow FDA approval

Drug reimbursement for medical oncology hospital outpatient departments remains at ASP plus 6%, and the drug-packaging threshold increased from USD 95-100; reimbursement for drug administration decreased. These fluctuation in reimbursement policies for cancer therapies is acting as a major restraint for the cancer therapy market.

Source: Prophecy Market Insights |Disclaimer: Data is only a representation. Actual data may vary in the final report.

Source: Prophecy Market Insights

Global Cancer CDK Inhibitor Market is segmented based on drug type, distribution channel, and region.

On the basis of Drug Type, Global Cancer CDK Inhibitor Market is segmented into Palbociclib, Ribociclib and Abemaciclib. Palbociclib is dominating in the drug type segment by the total share of 81.2%. Based on Distribution Channel, the target market is segmented into Hospital Pharmacies, Online Pharmacies and Others. Hospital pharmacies is dominating in this segment by sharing 52.5%.

Regional Insights:

On region Global Cancer CDK Inhibitor Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North American Cancer CDK Inhibitors Market accounted for a revenue share of 35.2% in 2019 and was valued at USD XX million, and is projected to reach USD XX million by 2029, growing at a CAGR of XX from 2019 to 2029.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2030 For the purpose of this study, has segmented Global Cancer CDK Inhibitor Market report based on drug type, distribution channel, and region.

Global Cancer CDK Inhibitor Market, By Region:

• • • North America
      • • U.S.
        • Canada
    • Europe
      • • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa

The key players operating in Global Cancer CDK Inhibitor Market includes Pfizer Inc., Novartis AG and Eli Lilly Roche, Sanofi, Astex Pharmaceuticals, Bristol-Myers Squibb, Onconova Therapeutics, Inc, AstraZeneca and Merck. Pfizer’s strategy includes active management of their portfolio, maximizing growth of core product segments, acquisitions to strengthen core areas of  portfolio- such as their recent acquisition of AstraZeneca’s small molecule  anti-infective business- and divestitures to increase focus on its core  strengths.

• Pfizer Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Novartis AG
• Eli Lilly
• Onconova Therapeutics, Inc
• Roche
• Sanofi
•  Astex Pharmaceuticals
•  Bristol-Myers Squibb
• AstraZeneca
•  Merck

“*” marked represents similar segmentation in other categories in the respective section